Omnicell price target lowered to $26 from $33 at Barclays

Barclays analyst Stephanie Davis lowered the firm’s price target on Omnicell to $26 from $33 and keeps an Underweight rating on the shares post the Q4 report. The stock was down 11% with weak fiscal 2023 bookings translating to a 2024 guidance miss, the analyst tells investors in a research note. The firm says that while the Q1 outlook looks conservative, it remains cautious on a second half weighted ramp.